Paper
RSC Advances
171.52, 170.35, 158.99, 158.78, 158.57, 158.35, 130.11, 127.84,
127.71, 124.17, 124.09, 121.32, 120.35, 118.37, 114.42, 111.03,
110.46, 110.40, 110.27, 62.18, 62.07, 60.60, 60.28, 60.14, 59.93,
55.53, 54.45, 53.32, 50.44, 49.96, 37.87, 37.62, 30.91, 29.49,
29.18, 27.24, 27.16, 24.72, 24.37, 23.94, 22.29, 22.22, 14.40. HR-
MS m/z calcd for C50H57B2N5O12 1090.5097, found [M + H]+
1091.5168, and found [M + Na]+ 1113.4976.
References
1 D. J. Craik, J. S. Mylne and N. L. Daly, Cell. Mol. Life Sci., 2010,
67, 9–16.
2 B. K. Chung and A. K. Yudin, Org. Biomol. Chem., 2015, 13,
8768–8779.
3 M. L. Colgrave and D. J. Craik, Biochemistry, 2004, 43, 5965–
5975.
4 J. Alegre-Cebollada, P. Kosuri, J. A. Rivaspardo and
Contryphan-Vn[1,9]
´
J. M. Fernandez, Nat. Chem., 2011, 3, 882–887.
Contryphan-Vn was obtained as a white lyophilized powder
(46.8 mg, 43% yield according to initial resin load, 97.2%
purity). 1H-NMR (300 MHz, d-DMSO): d 10.86–10.83 (m, 2H),
8.85–8.68 (m, 1H), 8.07–8.04 (m, 3H), 7.82–7.77 (m, 4H), 7.58–
7.54 (m, 2H), 7.33–7.31 (m, 2H), 7.22 (s, 2H), 7.17–7.13 (m, 2H),
7.07–7.04 (m, 2H), 6.99–6.95 (m, 2H), 4.68–4.52 (m, 2H), 4.49–
4.43 (m, 3H), 4.32–4.22 (m, 3H), 3.57 (s, 3H), 3.43–3.38 (m, 2H),
3.21–3.12 (m, 2H), 2.96–2.92 (m, 1H), 2.79–2.66 (m, 6H), 2.58–
2.52 (m, 2H), 2.20–2.17 (m, 1H), 2.00–1.91 (m, 2H), 1.76–1.74
(m, 4H), 1.64–1.47 (m, 6H), 1.29–1.23 (m, 5H). 13C-NMR (300
MHz, d-DMSO): d 172.61, 171.84, 171.59, 171.47, 171.22, 170.76,
169.75, 166.42, 166.14, 159.07, 158.42, 136.50, 136.46, 130.11,
127.79, 121.30, 118.74, 118.64, 116.26, 114.29, 111.79, 111.71,
110.48, 110.35, 60.36, 60.16, 55.63, 54.57, 54.03, 50.58, 50.06,
49.88, 47.75, 47.18, 36.57, 35.58, 31.00, 29.49, 29.14, 27.89,
27.56, 27.20, 25.85, 24.70, 24.30, 22.27, 14.40. HR-MS m/z calcd
for C50H65N13O11S2 1087.4368, found [M + H]+ 1088.4383.
5 L. Masip, J. L. Pan, S. Haldar, J. E. Penner-Hahn, M. P. Delisa,
G. Georqiou, J. C. Bardwell and J. F. Collet, Science, 2004, 303,
1185–1189.
6 H. M. Berman, J. Westbrook, Z. Feng, G. Gilliland, T. N. Bhat,
H. Weissig, I. N. Shindyalov and P. E. Bourne, Nucleic Acids
Res., 2000, 28, 235–242.
7 S. J. Moore, C. L. Leung and J. R. Cochran, Drug Discovery
Today: Technol., 2012, 9, e3–e11.
8 R. W. Busby, M. M. Kessler, W. P. Bartolini, A. P. Bryant,
G. Hannig, C. S. Higgins, R. M. Solinga, J. V. Tobin,
J. D. Wakeeld, C. B. Kurtz and M. G. Currie, J. Pharmacol.
Exp. Ther., 2013, 344, 196–206.
´
´
9 M. Gongora-Benıtez, J. Tulla-Puche and F. Albericio, Chem.
Rev., 2014, 114, 901–926.
10 R. G. Boy, W. Mier, E. M. Nothelfer, A. Altmann, M. Eisenhut,
¨
H. Kolmar, M. Tomaszowski, S. Kramer and U. Haberkorn,
Mol. Imaging Biol., 2010, 12, 377–385.
11 D. L. Rabenstein and K. H. Weaver, J. Org. Chem., 1996, 61,
7391–7397.
Reduction stability experiment
12 H. F. Gilbert, Methods Enzymol., 1995, 251, 8–28.
13 Z. Dekan, I. Vetter, N. L. Daly, D. J. Craik, R. J. Lewis and
P. F. Alewood, J. Am. Chem. Soc., 2011, 133, 15866–15869.
14 A. D. de Araujo, B. Callaghan, S. T. Nevin, N. L. Daly,
D. J. Craik, M. Moretta, G. Hopping, M. J. Christie,
D. J. Adams and P. F. Alewood, Angew. Chem., Int. Ed.
Engl., 2011, 50, 6527–6529.
Puried peptides (100 mg) was dissolved in 100 mL buffer
(20 mM Tris–HCl, pH ¼ 7.4, 150 mM NaCl, 1 mM CaCl2, 1 mM
MgCl2, 0.1% Triton X-100). DTT was added to a nal concen-
tration of 3 mM. Aer 0, 0.5, 1, 2, 4 and 8 hours' incubation at
ꢂ
25 C, the percent residual peptide was monitored by HPLC.
Protease stability experiment
15 A. D. de Araujo, M. Mobli, G. F. King and P. F. Alewood,
Angew. Chem., Int. Ed. Engl., 2012, 51, 10298–10302.
16 K. Holland-Nell and M. Meldal, Angew. Chem., Int. Ed. Engl.,
2011, 50, 5204–5206.
17 M. Empting, O. Avrutina, R. Meusinger, S. Fabritz,
M. Reinwarth, M. Biesalski, S. Voigt, G. Buntkowsky and
H. Kolmar, Angew. Chem., Int. Ed. Engl., 2011, 50, 5207–5211.
18 D. J. Derksen, J. L. Stymiest and J. C. Vederas, J. Am. Chem.
Soc., 2006, 128, 14252–14253.
Puried peptides was dissolved in DMSO to a nal concentra-
tion of 1 mM as solution A. a-Chymotrypsin was dissolved in
PBS buffer (pH ¼ 7.4, containing 2 mM CaCl2) to a nal
concentration of 0.5 ng mLꢀ1 as solution B. 50 mL solution A and
1950 mL solution B were mixed. Aer 0, 0.5, 1, 2, 4, 8, 16 and 32
hours' incubation at 25 ꢂC, the percent residual peptide was
monitored by HPLC.
19 H. K. Cui, Y. Guo, Y. He, F. L. Wang, H. N. Chang, Y. J. Wang,
F. M. Wu, C. L. Tian and L. Liu, Angew. Chem., Int. Ed. Engl.,
2013, 52, 9558–9562.
Conflicts of interest
There are no conicts to declare.
20 Y. Guo, D. M. Sun, F. L. Wang, Y. He, L. Liu and C. L. Tian,
Angew. Chem., Int. Ed. Engl., 2015, 54, 14276–14281.
21 F. L. Wang, Y. Guo, S. J. Li, Q. X. Guo, J. Shi and Y. M. Li, Org.
Biomol. Chem., 2015, 13, 6286–6290.
22 Y. Guo, C. Liu, H. Song, F. L. Wang, Y. Zou, Q. Y. Wu and
H. G. Hu, RSC Adv., 2017, 7, 2110–2114.
Acknowledgements
We thank LetPub for its linguistic assistance during the prep-
aration of this manuscript. We are grateful to the National
Natural Science Foundation of China (No. 81473301) and
Instrumental Analysis Centre of Second Military Medical
University for NMR spectroscopic and mass spectrometric
analyses.
This journal is © The Royal Society of Chemistry 2019
RSC Adv., 2019, 9, 5438–5444 | 5443